Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease
操纵帕金森病运动障碍中的基因表达
基本信息
- 批准号:9305587
- 负责人:
- 金额:$ 4.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAlternative TherapiesAnimal ModelAnimalsAntiparkinson AgentsAreaBasal GangliaBehaviorBehavioralBrainCellsChronicCorpus striatum structureDataDevelopmentDisciplineDopaminergic AgentsDyskinetic syndromeEvaluationExhibitsFrequenciesGene DeliveryGene ExpressionGene SilencingGene TransferGenesGlobus PallidusGoalsHealthImmunoblottingImmunohistochemistryInfusion proceduresInvoluntary MovementsLeadLevodopaLinkMediatingModelingMolecularMonkeysMotorNamesNeuronsOutcomeOutputParkinson DiseaseParkinsonian DisordersPatientsPharmacotherapyPhysiologicalPlayPrimatesProteinsProtocols documentationRNA InterferenceRattusRecombinant adeno-associated virus (rAAV)ResearchRodentRoleSmall Interfering RNASolidStructure of subthalamic nucleusTechnologyTestingTherapeuticTransgenic OrganismsViral Vectorabnormal involuntary movementclinical applicationdesigneffective therapyin vitro testingknock-downnonhuman primatenovel strategiesnovel therapeuticsoverexpressionprotein expressionreduce symptomsresearch studyresponsetooltranscription factortranslational study
项目摘要
DESCRIPTION (provided by applicant): This project addresses one of the most disabling complications of dopaminergic therapy in Parkinson's disease, namely the development of involuntary movements named dyskinesias. The mechanisms underlying dyskinesias remain unknown, and we lack specific and effective treatments to eradicate them. Studies in animal models have shown that the striatal levels of the chronic transcription factor ΔFosB consistently increase during chronic levodopa treatment. Therefore, it has been hypothesized that ΔFosB may regulate the genes responsible for altered responses to dopaminergic drugs. Here, we will test the effects of the transgenic manipulation of ΔFosB protein expression in non-human primates. The novel approach taken in this project may address pathophysiologic aspects and help develop new therapies. The project includes three specific aims. In the first aim, we will assess the behavioral and molecular changes following the overexpression of ΔFosB in the striatum of parkinsonian monkeys using a viral vector-mediated gene delivery. The second aim will examine the basal ganglia circuitry of these animals using electrophysiologic recordings and correlate them with the development of dyskinesias. And the third aim will confirm the role of ΔFosB by down-regulating the expression of the endogenous gene in rats and monkeys. This project employs diverse experimental approaches across disciplines to address an important health problem. From the construction of viral vectors, to the in vitro testing, to the final evaluations of motor behavior and physiologic correlates in primates, this sequence of translational studies is designed to establish the mechanistic role of ΔFosB in the development of dyskinesias. Furthermore, these studies will assess the clinical application of ΔFosB gene silencing as a therapeutic strategy in complicated Parkinson's disease.
描述(由适用提供):该项目介绍了帕金森氏病中多巴胺能疗法最残疾的并发症之一,即发展名为dyskinesias的非自愿运动的发展。动力障碍的基础机制仍然未知,我们缺乏对它们进行放射性修饰的特定和有效的治疗方法。动物模型中的研究表明,慢性转录因子的纹状体水平ΔFOSB在慢性左旋多巴治疗过程中始终增加。因此,已经假设ΔFOSB可以调节负责改变多巴胺能药物反应的基因。在这里,我们将测试非人类隐私中ΔFOSB蛋白表达的转基因操纵的作用。该项目采用的新方法可能会解决病理生理方面的问题并有助于开发新的疗法。该项目包括三个具体目标。在第一个目标中,我们将使用病毒载体介导的基因递送在帕金森猴纹状体中ΔFOSB过度表达后评估ΔFOSB过表达后的行为和分子变化。第二个目的将使用电生理记录检查这些动物的基本神经节电路,并将其与动态障碍的发展相关。第三个目标将通过下调大鼠和猴子中内源基因的表达来确认ΔFOSB的作用。该项目采用跨学科的潜水员实验方法来解决重要的健康问题。从病毒载体的构造,到体外测试,再到私人运动行为和生理相关性的最终评估,这一转化研究的序列旨在确定ΔFOSB在dyskinesias发展中的机械作用。此外,这些研究将评估ΔFOSB基因沉默作为复杂帕金森氏病的治疗策略的临床应用。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Letter from the Editor-in-Chief: Growth of the Journal.
主编的来信:期刊的成长。
- DOI:10.1007/s13311-019-00783-8
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Mouradian,MMaral
- 通讯作者:Mouradian,MMaral
Silica-coated magnetic-nanoparticle-induced cytotoxicity is reduced in microglia by glutathione and citrate identified using integrated omics.
- DOI:10.1186/s12989-021-00433-y
- 发表时间:2021-11-25
- 期刊:
- 影响因子:10
- 作者:Shin TH;Manavalan B;Lee DY;Basith S;Seo C;Paik MJ;Kim SW;Seo H;Lee JY;Kim JY;Kim AY;Chung JM;Baik EJ;Kang SH;Choi DK;Kang Y;Mouradian MM;Lee G
- 通讯作者:Lee G
Silica-coated magnetic nanoparticles impair proteasome activity and increase the formation of cytoplasmic inclusion bodies in vitro.
- DOI:10.1038/srep29095
- 发表时间:2016-07-05
- 期刊:
- 影响因子:4.6
- 作者:Phukan G;Shin TH;Shim JS;Paik MJ;Lee JK;Choi S;Kim YM;Kang SH;Kim HS;Kang Y;Lee SH;Mouradian MM;Lee G
- 通讯作者:Lee G
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M. Maral Mouradian其他文献
M. Maral Mouradian的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('M. Maral Mouradian', 18)}}的其他基金
PME-1: Pathogenetic Role and Therapeutic Opportunity in Neurodegenerative Mixed Proteinopathies
PME-1:神经退行性混合蛋白病的致病作用和治疗机会
- 批准号:
10595891 - 财政年份:2023
- 资助金额:
$ 4.8万 - 项目类别:
Alzheimer’s Disease Protection by Reduced Adenylyl Cyclase Type 5
通过减少 5 型腺苷酸环化酶来预防阿尔茨海默病
- 批准号:
10526756 - 财政年份:2022
- 资助金额:
$ 4.8万 - 项目类别:
Role of Transglutaminase 2 in Synucleinopathies
转谷氨酰胺酶 2 在突触核蛋白病中的作用
- 批准号:
10285001 - 财政年份:2021
- 资助金额:
$ 4.8万 - 项目类别:
Training in Translating Neuroscience to Therapies
将神经科学转化为治疗的培训
- 批准号:
10442401 - 财政年份:2021
- 资助金额:
$ 4.8万 - 项目类别:
Training in Translating Neuroscience to Therapies
将神经科学转化为治疗的培训
- 批准号:
10204266 - 财政年份:2021
- 资助金额:
$ 4.8万 - 项目类别:
Training in Translating Neuroscience to Therapies
将神经科学转化为治疗的培训
- 批准号:
10621360 - 财政年份:2021
- 资助金额:
$ 4.8万 - 项目类别:
PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies
α-突触核蛋白病发病机制中的 PP2A 失调
- 批准号:
9920223 - 财政年份:2017
- 资助金额:
$ 4.8万 - 项目类别:
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas
咖啡成分对帕金森病的协同神经保护机制
- 批准号:
8700581 - 财政年份:2012
- 资助金额:
$ 4.8万 - 项目类别:
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas
咖啡成分对帕金森病的协同神经保护机制
- 批准号:
8368832 - 财政年份:2012
- 资助金额:
$ 4.8万 - 项目类别:
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas
咖啡成分对帕金森病的协同神经保护机制
- 批准号:
8543640 - 财政年份:2012
- 资助金额:
$ 4.8万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10600887 - 财政年份:2023
- 资助金额:
$ 4.8万 - 项目类别:
The Use of Blood Cells and Optical Cerebral Complex IV Redox States in a Porcine Model of CO Poisoning with Evaluation of Mitochondrial Therapy
血细胞和光脑复合物 IV 氧化还原态在猪 CO 中毒模型中的应用及线粒体治疗的评价
- 批准号:
10734741 - 财政年份:2023
- 资助金额:
$ 4.8万 - 项目类别:
Novel risk stratification score for patients presenting with acute Cerebral Venous Sinus Thrombosis
急性脑静脉窦血栓形成患者的新风险分层评分
- 批准号:
10592974 - 财政年份:2023
- 资助金额:
$ 4.8万 - 项目类别:
Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections
用于治疗耐抗生素肺炎克雷伯菌感染的先导治疗噬菌体混合物的优化、制造和测试
- 批准号:
10674294 - 财政年份:2023
- 资助金额:
$ 4.8万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10917559 - 财政年份:2023
- 资助金额:
$ 4.8万 - 项目类别: